We've got you covered
We are here to guide you in making tough decisions with your hard earned money. Drop us your details and we will reach you for a free one on one discussion with our experts.
or
Call us on: +917410000494
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
TODAY'S HIGH
663.95
TODAY'S LOW
646.05
52 WEEK HIGH
993.95
52 WEEK LOW
607.75
% of Shares Held by
All Insider
51.38%
% of Shares Held by
Institutions
19.89%
% of Float Held by
Institutions
40.92%
Number of Institutions
Holding Shares
50
MARKET CAP
11953.83 Cr.
ETERPRISE VALUE
11433.88 Cr.
NO. OF SHARES
18.25 Cr.
BOOK VALUE
233.865
DIV. YIELD
3.5%
DEBT
415.50 Cr.
GROSS PROFIT
1823.90 Cr.
CASH
799.90 Cr.
REVENUE
2419.10 Cr.
REVENUE/SHARE
132.609
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Investments | 203.90 Cr. | 36.20 Cr. | 82.10 Cr. | -218.70 Cr. |
| Change To Liabilities | 7.40 Cr. | -109.50 Cr. | 41.70 Cr. | -51.20 Cr. |
| Total cashflows from Investing Activities | -5.30 Cr. | -103.30 Cr. | -167 Cr. | -612.20 Cr. |
| Net Borrowings | 135.80 Cr. | -49.60 Cr. | -80.90 Cr. | 213.10 Cr. |
| Total Cash from Financing Activities | 34.80 Cr. | -185.70 Cr. | -250.80 Cr. | -50.90 Cr. |
| Other Liabilities | -56.30 Cr. | 6.20 Cr. | -56.60 Cr. | 11.60 Cr. |
| Total Assets | 0 | 10 Lakhs | 47.50 Cr. | 47.50 Cr. |
| Net Income | 170 Cr. | 440.90 Cr. | 460.80 Cr. | 644.40 Cr. |
| Change in Cash | 85.30 Cr. | 6 Cr. | -8.50 Cr. | 6.60 Cr. |
| Effect of Exchange Rate | 9.30 Cr. | -3.80 Cr. | -8 Cr. | 90 Lakhs |
| Total Cash from Operating Activities | 46.50 Cr. | 298.80 Cr. | 417.30 Cr. | 668.80 Cr. |
| Depreciation | 142.60 Cr. | 114.50 Cr. | 97.30 Cr. | 78.70 Cr. |
| Other Cashflows from Investing Activities | 82.30 Cr. | 67.10 Cr. | 87.40 Cr. | 52.40 Cr. |
| Dividends Paid | -82.20 Cr. | -113.90 Cr. | -127.40 Cr. | -91.90 Cr. |
| Change to Inventory | 56.40 Cr. | -240.20 Cr. | -28.90 Cr. | -90.60 Cr. |
| Change to Account Receivables | -238.90 Cr. | 130.60 Cr. | -53.80 Cr. | 138.80 Cr. |
| Other Cashflows from Financing Activities | -18.80 Cr. | -22.30 Cr. | -36.40 Cr. | -37.40 Cr. |
| Change to Net Income | -34.70 Cr. | -46.10 Cr. | -45.70 Cr. | -65.20 Cr. |
| Capital Expenditures | -232.70 Cr. | -254.60 Cr. | -355.70 Cr. | -456.60 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Research Development | None | None | None | None |
| Effect of Accounting Charges | None | None | None | None |
| Income Before Tax | 202.20 Cr. | 579.60 Cr. | 568.70 Cr. | 824.70 Cr. |
| Minority Interest | 0 | 1.80 Cr. | 11.20 Cr. | 2 Cr. |
| Net Income | 120.90 Cr. | 493.30 Cr. | 485.70 Cr. | 716 Cr. |
| Selling General Administrative | 444.80 Cr. | 439 Cr. | 471.90 Cr. | 444.60 Cr. |
| Gross Profit | 1383.90 Cr. | 1524.30 Cr. | 1509 Cr. | 1712.70 Cr. |
| Ebit | 120.90 Cr. | 493.30 Cr. | 485.70 Cr. | 716 Cr. |
| Operating Income | 120.90 Cr. | 493.30 Cr. | 485.70 Cr. | 716 Cr. |
| Other Operating Expenses | 675.60 Cr. | 463.40 Cr. | 446.10 Cr. | 469.40 Cr. |
| Interest Expense | -17.70 Cr. | -8.80 Cr. | -17.70 Cr. | -16.20 Cr. |
| Extraordinary Items | None | None | None | None |
| Non Recurring | None | None | None | None |
| Other Items | None | None | None | None |
| Income Tax Expense | 32.20 Cr. | 137.20 Cr. | 110.60 Cr. | 182.30 Cr. |
| Total Revenue | 1944.80 Cr. | 2056.10 Cr. | 1915 Cr. | 2094.50 Cr. |
| Total Operating Expenses | 1823.90 Cr. | 1562.80 Cr. | 1429.30 Cr. | 1378.50 Cr. |
| Cost of Revenue | 560.90 Cr. | 531.80 Cr. | 406 Cr. | 381.80 Cr. |
| Total Other Income Expense Net | 81.30 Cr. | 86.30 Cr. | 83 Cr. | 108.70 Cr. |
| Discontinued Operations | None | None | None | None |
| Net Income from Continuous Ops. | 170 Cr. | 442.40 Cr. | 458.10 Cr. | 642.40 Cr. |
| Net Income Applicable to Common Shares | 170 Cr. | 440.90 Cr. | 460.80 Cr. | 644.40 Cr. |
| Particulars | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 |
|---|---|---|---|---|
| Intangible Assets | 82.20 Cr. | 9.40 Cr. | 8.80 Cr. | 8.70 Cr. |
| Capital Surplus | 0 | 1391.50 Cr. | 1372.90 Cr. | 1404.80 Cr. |
| Total Liabilities | 845.50 Cr. | 668.50 Cr. | 803.10 Cr. | 812.10 Cr. |
| Stock Holder Equity | 4263.60 Cr. | 4121.60 Cr. | 3773.50 Cr. | 3489 Cr. |
| Minority Interest | 0 | 1.80 Cr. | 11.20 Cr. | 2 Cr. |
| Other Liabilities | 124.10 Cr. | 48.40 Cr. | 56.80 Cr. | 79.90 Cr. |
| Total Assets | 5109.10 Cr. | 4791.90 Cr. | 4587.80 Cr. | 4303.10 Cr. |
| Common Stock | 36.50 Cr. | 36.50 Cr. | 36.40 Cr. | 36.50 Cr. |
| Retained Earnings | 0 | 2627.70 Cr. | 2298.60 Cr. | 1996.60 Cr. |
| Other Liabilities | 127.10 Cr. | 142 Cr. | 116.90 Cr. | 83.40 Cr. |
| Good Will | 50.70 Cr. | 0 | 0 | 0 |
| Treasury Stock | 4227.10 Cr. | 65.90 Cr. | 65.60 Cr. | 51.10 Cr. |
| Other Assets | 66.20 Cr. | 48.60 Cr. | 76.20 Cr. | 71.20 Cr. |
| Cash | 206.10 Cr. | 25.80 Cr. | 19.80 Cr. | 28.30 Cr. |
| Current Liabilities | 710.40 Cr. | 525.60 Cr. | 685.30 Cr. | 728.70 Cr. |
| Long Term Asset Charges | 0 | 0 | 0 | 0 |
| Short Long Term Debt | 0 | 0 | 0 | 0 |
| Other Stockholder Equity | 4227.10 Cr. | 65.90 Cr. | 65.60 Cr. | 51.10 Cr. |
| Property Plant Equipment | 2308.40 Cr. | 2237.20 Cr. | 2093.60 Cr. | 1856.10 Cr. |
| Total Cur. Assets | 2497.20 Cr. | 2337.30 Cr. | 2325.60 Cr. | 2347.20 Cr. |
| Long Term Investments | 104.40 Cr. | 159.40 Cr. | 83.60 Cr. | 19.90 Cr. |
| Net Tangible Assets | 4130.70 Cr. | 4112.20 Cr. | 3764.70 Cr. | 3480.30 Cr. |
| Short Term Investments | 593.80 Cr. | 784.40 Cr. | 882.70 Cr. | 1029.30 Cr. |
| Net Receivables | 631 Cr. | 498.10 Cr. | 633.30 Cr. | 606.80 Cr. |
| Long Term Debt | 0 | 0 | 0 | 0 |
| Inventory | 762 Cr. | 910.40 Cr. | 698.70 Cr. | 590.80 Cr. |
| Accounts Payable | 161.80 Cr. | 146.20 Cr. | 255.40 Cr. | 217 Cr. |
Open a demat account through us and get the account opening charges waived off
open paperless account